ReNeuron Group plc Board change (4399L)

TIDMRENE

RNS Number : 4399L

ReNeuron Group plc

19 July 2017

 
 AIM: RENE     19 July 
                2017 
 

ReNeuron Group plc

Board change

ReNeuron Group plc (the "Company") (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, today announces that Dr Paul Harper, a non-executive director of the business since the Company's flotation on AIM in 2005, will step down from the Board at the next Annual General Meeting of the Company, which will take place in early September this year. During his tenure on the Board, Dr Harper has played an instrumental role in guiding the Company through its early development and into its clinical development phase.

The Company intends to appoint a further non-executive to the Board and will make an announcement in this regard in due course.

John Berriman, Chairman of ReNeuron, said:

"I would like to thank Paul for the immense contribution he has made to the Company's success over his long tenure on the Board. His expertise and experience have been invaluable to us over the years and, on behalf of the Board and staff of the Company, we wish Paul all the best in his future endeavours."

ENDS

ENQUIRIES:

 
ReNeuron                                                            [phone] 
Olav Hellebø , Chief Executive Officer 
Michael Hunt, Chief Financial Officer 
Buchanan                                                            [phone] 
Mark Court, Sophie Cowles, Stephanie Watson 
 
Stifel Nicolaus Europe Limited                                      [phone] 
Jonathan Senior, Stewart Wallace, Ben Maddison (NOMAD and Broker) 
 

About ReNeuron

ReNeuron is a leading, clinical-stage cell therapy development company. Based in the UK, its primary objective is the development of novel cell-based therapies targeting areas of significant unmet or poorly met medical need.

ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered "off-the-shelf" to any eligible patient without the need for additional immunosuppressive drug treatments. The Company has therapeutic candidates in clinical development for motor disability as a result of stroke, for critical limb ischaemia and for the blindness-causing disease, retinitis pigmentosa.

ReNeuron is also advancing its proprietary exosome technology platform as a potential new nanomedicine targeting cancer and as a potential delivery system for drugs that would otherwise lack adequate capacity to penetrate to their site of action.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. Further information on ReNeuron and its products can be found at www.reneuron.com.

This announcement contains forward-looking statements with respect to the financial condition, results of operations and business achievements/performance of ReNeuron and certain of the plans and objectives of management of ReNeuron with respect thereto. These statements may generally, but not always, be identified by the use of words such as "should", "expects", "estimates", "believes" or similar expressions. This announcement also contains forward-looking statements attributed to certain third parties relating to their estimates regarding the growth of markets and demand for products. By their nature, forward-looking statements involve risk and uncertainty because they reflect ReNeuron's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of factors could cause ReNeuron's actual financial condition, results of operations and business achievements/performance to differ materially from the estimates made or implied in such forward-looking statements and, accordingly, reliance should not be placed on such statements.

This information is provided by RNS

The company news service from the London Stock Exchange

END

BOARPMMTMBABTBR

(END) Dow Jones Newswires

July 19, 2017 02:00 ET (06:00 GMT)